Literature DB >> 18807129

Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel.

Fook Hong Ng1, Pierre Chan, Chi Pong Kwanching, Ching Kong Loo, Ting Kin Cheung, Siu Yin Wong, Carolyn Kng, Ka Man Ng, Sik To Lai, Benjamin Chun Yu Wong.   

Abstract

BACKGROUND: This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy.
METHODS: From January 2002 to September 2006, patients with endoscopically proven peptic ulcers/erosions after receiving A + C cotherapy were analyzed.
RESULTS: This group consisted of 106 patients (age, 69.3 +/- 11.7 years). Ulcers/erosions developed in 27 patients during hospitalization for cardiac events and in 79 patients after hospital discharge. Of 27 patients hospitalized for acute cardiac events, gastrointestinal (GI) bleeding and dyspepsia occurred in 24 and three, respectively. The most common lesion was gastric ulcer. Of 79 discharged patients, GI bleeding and dyspepsia occurred in 64 and 15, respectively. The most common bleeding and dyspeptic lesions were gastric ulcer and gastritis, respectively. Overall, 17 patients underwent endoscopic hemostasis all successfully. A + C cotherapy was continued in 57 patients for a median (interquartile range) of 3.0 (6.2) months. Most were coprescribed a proton pump inhibitor (PPI) (53, 93%). No recurrent GI bleeding was observed.
CONCLUSIONS: After A + C cotherapy, gastric ulcer or gastritis were the most common endoscopic lesions. The combination of a PPI and endoscopic treatment for ulcer bleeding was highly successful. After patient stabilization, continuation of A + C cotherapy with a PPI appears to be safe.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807129     DOI: 10.1007/s00535-008-2215-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  22 in total

1.  The risk associated with aprotinin in cardiac surgery.

Authors:  Dennis T Mangano; Iulia C Tudor; Cynthia Dietzel
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

2.  Trading restenosis for thrombosis? New questions about drug-eluting stents.

Authors:  Miriam Shuchman
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

3.  Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.

Authors:  Fook-Hong Ng; Kwok-Fai Lam; Siu-Yin Wong; Chee-My Chang; Yuk-Kong Lau; Wai-Cheung Yuen; Wai-Ming Chu; Benjamin C Y Wong
Journal:  Digestion       Date:  2008-06-25       Impact factor: 3.216

4.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.

Authors:  Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Przemyslaw P Borek; Girish R Mood; Deepak L Bhatt
Journal:  Am J Med       Date:  2006-12       Impact factor: 4.965

5.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study.

Authors:  Jesper Hallas; Michael Dall; Alin Andries; Birthe Søgaard Andersen; Claus Aalykke; Jane Møller Hansen; Morten Andersen; Annmarie Touborg Lassen
Journal:  BMJ       Date:  2006-09-19

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  Safety and efficacy of esophagogastroduodenoscopy after myocardial infarction.

Authors:  M S Cappell; F M Iacovone
Journal:  Am J Med       Date:  1999-01       Impact factor: 4.965

9.  Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study.

Authors:  Marcus W S Chin; Gerald Yong; Max K Bulsara; Jamie Rankin; Geoffrey M Forbes
Journal:  Am J Gastroenterol       Date:  2007-09-10       Impact factor: 10.864

10.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Authors:  A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin
Journal:  J Am Coll Cardiol       Date:  1988-01       Impact factor: 24.094

View more
  4 in total

1.  Risk factors and prevention of upper gastrointestinal hemorrhage after a coronary artery bypass grafting operation.

Authors:  Hongguang Fan; Zhe Zheng; Wei Feng; Wei Wang; Yunhu Song; Ye Lin; Shengshou Hu
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

Review 2.  Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy.

Authors:  Hiroshi Yasuda; Yasumasa Matsuo; Yoshinori Sato; Sun-Ichiro Ozawa; Shinya Ishigooka; Masaki Yamashita; Hiroyuki Yamamoto; Fumio Itoh
Journal:  World J Crit Care Med       Date:  2015-02-04

3.  The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.

Authors:  Muhammad Ali Khan; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

4.  Recent advances in peptic ulcer bleeding.

Authors:  Ian Lp Beales
Journal:  F1000 Med Rep       Date:  2009-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.